Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
09/13/2019
Trade Name:
Mydayis
Generic Name or Proper Name (*):
mixed salts of a single-entity amphetamine
Indications Studied:
Attention Deficit Hyperactivity Disorder (ADHD)
Label Changes Summary:
*Safety and effectiveness have not been established in pediatric patients ages 12 years and younger. *Mydayis has been studied for the treatment of ADHD in pediatric patients 6 to 12 years in two placebo-controlled safety and efficacy trials. *In the first trial, pediatric patients 6 to 12 years experienced higher rates of adverse reactions in some cases compared to patients 13 years and older, including higher rates of insomnia (30% versus 8%) and appetite decreased (43% versus 22%). *Amphetamine systemic exposures in pediatric patients 6 to 12 years following a single dose were higher than those observed in adults at the same dose (72-79% higher Cmax and approximately 83% higher AUC). A second trial evaluated a lower dose than those approved for pediatric patients 13 to 17 years; efficacy was not demonstrated for the lower dose. *A safe and effective dose cannot be established in pediatric patients 12 years and younger. *Information on adverse reactions, PK parameters, and clinical trials. *Postmarketing requirement.
BPCA(B) and PREA(P):
B,P
Sponsor:
Shire
Pediatric Exclusivity Granted Date:
08/18/2019
NNPS:
FALSE
Therapeutic Category:
CNS Stimulant
-
-